The 5'¯anking region of the C3(1) component of the rat prostate steroid binding protein (PSBP) has been used to successfully target the expression of the SV40 large Tantigen (Tag) to the epithelium of both the mammary and prostate glands resulting in models of mammary and prostate cancers which histologically resemble the human diseases. Atypia of the mammary ductal epithelium develops at about 8 weeks of age, progressing to mammary intraepithelial neoplasia (resembling human ductal carcinoma in situ [DCIS]) at about 12 weeks of age with the development of invasive carcinomas at about 16 weeks of age in 100% of female mice. The carcinomas share features to what has been classi®ed in human breast cancer as in®ltrating ductal carcinomas. All FVB/N female mice carrying the transgene develop mammary cancer with about a 15% incidence of lung metastases. Approximately 10% of older male mice develop anaplastic mammary carcinomas. Unlike many other transgenic models in which hormones and pregnancy are used to induce a mammary phenotype, C3(1)/Tag mice develop mammary tumors in the mammary epithelium of virgin animals without hormone supplementation or pregnancy. Although mammary tumor development appears hormone-responsive at early stages, invasive carcinomas are hormone-independent, which corresponds to the loss of estrogen receptor-a expression during tumor progression. Molecular and biologic factors related to mammary tumor progression can be studied in this model since lesions evolve over a predictable time course. Genomic alterations have been identi®ed during tumor progression, including an ampli®cation of the distal portion of chromosome 6 containing ki-ras and loss of heterozygosity (LOH) in other chromosomal regions. We have demonstrated that stage speci®c alterations in the expression of genes which are critical regulators of the cell cycle and apoptosis are functionally important in vivo. C3(1)/Tag mice appear useful for testing particular therapies since growth of the mammary tumors can be reduced using chemopreventive agents, cytokines, and an anti-angiogenesis agent.
Introduction
The application of transgenic technology to study mammary gland biology and cancer has proven extremely powerful for understanding important principles of transformation and for modeling cancer in a rodent system (Furth et al., 1998; Macleod and Jacks, 1999; Merlino, 1994) . Numerous transgenic studies, including those reviewed in this journal issue, have demonstrated how perturbations in the expression of oncogenes, growth factors, and receptors may alter normal mammary development and lead to cancer.
The vast majority of these models have been developed using either the mouse mammary tumor virus (MMTV) or whey acidic protein (WAP) promoter/enhancer to direct heterologous gene expression to the mammary gland (see Cardi et al., 2000, this issue; Amundadottir et al., 1996) . Transcriptional activity of the MMTV and WAP promoters is often dependent on and highly responsive to pregnancy or administration of hormones (Pittius et al., 1988; Cato et al., 1989) . Pregnancy dependent transgenic models of mammary cancer are dissimilar to human breast cancer in which pregnancy has been identi®ed as a protective factor. This suggests that transcriptional activity of MMTV or WAP tends to be higher in hormonestimulated, dierentiated mammary epithelial cells. For this reason, these promoters are not well suited to study the in¯uence of hormones on mammary oncogenesis since hormones will modulate the levels of transgene expression. In addition, expression driven from the MMTV promoter is often sporadic throughout the mammary gland (Stamp et al., 1992) . Therefore, the development of additional hormoneindependent promoters to direct expression to the mammary epithelium will be advantageous for transgenic modeling in the mammary gland.
Characterization of the mammary phenotype in transgenic mice carrying the PSBP C3(1) 5'¯anking sequence to drive expression of Tag has revealed interesting features relevant to the study of human breast cancer (Maroulakou et al., 1994; Shibata et al., 1996a Shibata et al., , 1999 . Since the C3(1) vector appears to target expression to the mammary epithelium dierently than the MMTV or WAP promoters, the resulting mammary tumor phenotype has some unique features.
Originally, the C3(1)/Tag construct was designed to direct expression of Tag to the prostate epithelium of transgenic mice. C3(1)/Tag transgenic male mice, in fact, do develop phenotypic changes which highly resemble human prostatic intraepithelial neoplasia progressing to invasive carcinoma (Maroulakou et al., 1994 , Shibata et al., 1996b . In addition, tumors of the urethral/bulbourethral and salivary glands were also observed in further detailed studies (Shibata et al., 1998a) . However, 100% of female mice carrying the same transgene develop mammary carcinomas with some histologic similarities to human breast cancer. This model has been extremely useful for studying various aspects of mammary tumor progression, including changes in genomic organization, cell cycle regulation, apoptosis, and the in¯uences of hormones on the natural history of tumor development. Chemoprevention agents, cytokine therapy, and an anti-angiogenesis agent have also been successfully used to suppress mammary tumor progression in the C3(1)/Tag transgenic mice.
Regulation of the rat prostate steroid binding protein C3(1) gene
In order to understand the transgenic expression pattern of the C3(1)/Tag transgene, it is helpful to review what is known about the regulation of the C3(1) gene, a subunit of PSBP. PSBP is the most highly secreted protein of the rat ventral prostate (Heyns and DeMoor, 1977) . Previous transgenic experiments by Allison et al. (1989) demonstrated that all of the elements necessary to recapitulate the pattern of endogenous C3(1) expression in the rat are contained within an 8 kb genomic fragment which includes 4 kb of 5'¯anking sequence, three exons and 2 kb of sequence downstream of the polyadenylation site. Several in vitro studies have de®ned the location of various cis-acting elements, including androgen response elements (AREs). Although it has been shown that androgen receptor binds to elements contained within the promoter region as well as in the ®rst intron (Rushmere et al., 1987) , only the ARE contained within the ®rst intron has been shown to be functionally responsive to androgen resulting in increased levels of transcription Claessens et al., 1990; Tan et al., 1992) . Studies in which up to 8 kb of the C3(1) 5'¯anking sequence were fused to the Cat reporter gene did not demonstrate any transcriptional response to androgen in co-transfection experiments Claessens et al., 1990; Tan et al., 1992) . There is no evidence that estrogen is able to activate C3(1) transcription, although few studies have addressed this issue (Vanaken et al., 1996) . The C3(1)/Tag transgenic construct which we developed contains 4.5 kb of the C3(1) 5'¯anking region without intronic sequences. Thus, it is possible that the expression of this transgene is regulated primarily by tissue-speci®c cis-acting elements contained within the 5'¯anking region rather than by responsiveness to androgens.
It remains unclear why this transgene expresses in the mammary epithelium when the rat PSBP gene was thought to be primarily prostate speci®c. It is possible that low levels of C3(1) expression may normally occur in the rat mammary gland.
Recent studies have suggested that the C3(1) gene is part of a family of proteins which shares common protein motifs with other genes including mammoglobin, uteroglobin, CC10, and male mouse salivary gland protein (Watson and Fleming, 1996) . As a member of the mammoglobin family, it is possible that the C3(1) 5'¯anking region contains some cis-acting elements which target expression to the mammary gland. It is also possible that the transgene lacks regulatory elements contained downstream of the C3(1) transcriptional start site that act as tissue speci®c silencers that further de®ne tissue speci®city.
Other groups have also used various forms of C3(1) as a transgenic targeting vectors to overexpress polyoma middle T-antigen (Py-MT) (Tehranian et al., 1996) and Bcl-2 (Zhang et al., 1997) . The C3(1)/Py-MT construct used a 4.4 kb fragment of C3(1) which included about 3 kb of the 5'¯anking sequence and the ®rst intron. Py-MT was expressed in the mammary and prostate glands as well as the lung, parotid glands and heart. The C3(1) regulatory regions used in the C3(1)/Bcl-2 construct were similar to those used in the C3(1)/Py-MT construct except it contained about 1.3 kb more 5'¯anking sequence. Bcl-2 expression was observed in the prostate, testes and uterus but was not examined in the mammary gland.
As discussed below, the C3(1)/Tag transgene is expressed primarily in the distal mammary ductal epithelium and terminal ductal lobular unit (TDLU) units leading to the progressive development of mammary cancers.
Action of SV40 Tag
The early region of SV40 produces both large T-and small t-antigen proteins involved in cellular transformation (Cole, 1998; Moens et al., 1997) . Large Tag has been well characterized and used as a powerful transforming agent in numerous cell types both in vitro and in vivo. Although the expression of SV40 Tag has not been correlated to human breast cancer, studies have demonstrated that Tag-related transcripts may be expressed in mesotheliomas (Carbone et al., 1999) and human brains tumors (Martini et al., 1998) , suggesting that Tag may be involved in the etiology of these tumors.
The mechanisms by which Tag induces transformation and tumorigenesis is thought to involve its ability to bind to and functionally inactivate p53 (Mietz et al. 1992) and Rb (Dyson et al., 1989) , two tumor suppressor genes critical for maintaining homeostasis of cell growth. Many human cancers, including breast cancer, have been found to contain mutations or deletions which inactivate these tumor suppressor genes (Cox et al., 1994) leading to abnormalities in cell cycle regulation, increased cellular proliferation, and defects in the activation of apoptosis pathways. Thus, the Taginduced transformation process involves the inactivation of critical growth control pathways that are also commonly altered in human cancers. This suggests that the induction of tumorigenesis by Tag in this transgenic model may utilize mechanistic pathways that are also involved in the development of human breast cancers.
Natural history and histologic progression of mammary tumors
The phenotypic abnormalities observed in the C3(1)/ Tag mice correlate directly to the expression of Tag C3(1)/Tag transgenic mammary cancer JE Green et al (Figure 1 ; Maroulakou et al., 1994; Shibata et al., 1996a,b) . Mammary tumor development is the predominant phenotype in C3(1)/Tag female mice, although female transgenic mice surviving beyond 5 months of age also occasionally develop mixed tumors originating from sweat glands located in the foot pads (Maroulakou et al., 1999) , mild proliferative changes in the salivary glands (Shibata et al., 1998a) , and occasionally tumors arising from the vomeronasal organ (Maroulakou et al., 1994) .
The earliest observable mammary lesion is atypia of the ductal epithelial cells observed beginning at about 8 weeks of age (Figure 2a) , suggesting the eect of Tag on nuclear morphology occurs quite early. These atypical cells likely represent the earliest stage of mammary intraepithelial neoplasia (MIN), low grade. As well as occurring in ducts, atypical epithelium can also be present in the TDLU (Figures 2d,e and 3a) . Atypical lesions progress to high grade MIN beginning at about 12 weeks of age (Figure 2b,c) . In prior publications we designated these lesions as nodular atypical hyperplasias (NAH). The hyperchromatic atypical cells lose polarity and form masses which extend into the duct lumen. Larger intraepithelial neoplastic lesions ®ll the duct lumen but do not invade the basement membrane; these lesions appear similar to human DCIS ( Figure 2c ). As seen in whole mounts, MIN may be focal or multifocal (Figure 3) . MIN often progress into invasive carcinoma (Figures 2f ± h and 3d) beginning at about 16 weeks of age at which time, tumors are grossly palpable. Carcinoma formation is multifocal with females over 5 months of age commonly developing several grossly palpable tumors. Tumors tend to arise earlier in the axillary glands, but all mammary glands are usually aected. Due to the rapid growth of large mammary tumors, females are euthanized by 7 months of age. Male and female mice heterozygous or homozygous for the transgene are fertile, but ospring from homozygous females must be fostered since mothers homozygous for the transgene are unable to lactate suciently to support their pups.
The lung is the predominant site for metastases in this transgenic model (Figure 2i ), although metastases to the liver, adrenal and heart have been observed. Metastases to the brain, bone, and regional lymph nodes have not been observed demonstrating a major biologic dierence between the behavior of the C3(1)/ Tag transgenic mouse tumors and human breast cancer. As in the case of several other transgenic models, metastases to the lung are often of a vascular embolic type where metastatic lesions arise from hematogenously spread tumor cell emboli that generally grow within the blood vessels of the lung although they also invade vessel walls and lung parenchyma (Figure 2i ). C3(1)/Tag mammary tumors have been observed to directly invade adjacent lymph nodes (Figure 2g ), skeletal muscle (Figure 2h) , salivary glands and skin.
Genetic variation between mouse strains can alter the natural history of tumor formation and metastases in mice carrying the C3(1)/Tag transgene. Tumor progression is 1 ± 2 months slower in the C57B6 strain of mice compared to FVB/N mice carrying the C3(1)/ Tag transgene. Whereas we observe a 10 ± 15% incidence of lung metastases in the FVB/N background, over 50% of mice with the hybrid SV129 FVB/N background carrying the C3(1)/Tag transgene develop lung metastases (Maroulakou et al., 1997) . These observations suggest that genetic modi®ers are important modulators of phenotypic expression of the mammary tumors in this transgenic model.
Genomic changes during tumor progression
Numerous genomic alterations have been characterized in many human mammary tumors and have led to this discovery of genes involved in oncogenesis. These alterations may be observed as the gross loss or gain of chromosomal material, chromosomal rearrangements, localized deletions identi®ed by LOH, or speci®c gene mutations.
Comparative genomic hybridization has revealed that mammary tumor progression in the C3(1)/Tag transgenic mice is associated with a gain of genomic material from the distal region of mouse chromosome 6 (Liu et al., 1998) . We have demonstrated by Southern blot analyses that the ki-ras gene, which is contained within this region of chromosome 6, is ampli®ed up to 30-fold. Furthermore, the amplification of ki-ras correlates with increased expression of ki-ras RNA and protein and is associated with increased MAP kinase activity (Liu et al., 1998) . In order to determine whether the ampli®cation and overexpression of ki-ras is functionally important for tumor progression in this model, mice carrying the C3(1)/Tag transgene and lacking one allele of ki-ras were generated and studied. Through these studies we have demonstrated that ki-ras is indeed functionally important in accelerating mammary tumor progression. Mice lacking one normal allele of ki-ras have retarded tumor development compared to C3(1)/Tag mice with both wild type alleles of ki-ras which is not due to dierences in strain background (Liu et al., manuscript in preparation) .
Ongoing LOH studies indicate that several genomic loci on dierent chromosomes may harbor suppressor genes whose function is lost during mammary tumor progression in this transgenic model. Further studies using spectral karyotyping may reveal additional changes in chromosomal structure during tumor progression.
Molecular alterations during tumor progression
Tag is expressed in all tissues which develop proliferative lesions in the transgenic mice. RNA in situ hybridization and immunohistochemistry ( Figure  1 ) demonstrate that Tag expression in the mammary gland is localized to the ductal epithelium and TLDU (Maroulakou et al., 1994; Shibata et al., 1996a) . The levels of Tag protein appear to correlate directly with the levels of Tag mRNA. The entire early region of SV40 was used in the transgenic construct and contains both large T-antigen and small t-antigen (t). The appropriate RNA species for small-t antigen is made in the mammary epithelium. However, the role of small t in mammary tumor development in this model remains unclear, although it may be important for inducing tumor progression (Choi et al., 1988) .
The mechanism for Tag-induced transformation includes the binding of this oncoprotein to two critical tumor suppressor genes, p53 and Rb, leading to their functional inactivation. Although p53 and Rb are functionally impaired by Tag, immunohistochemical studies of the C3(1)/Tag mammary tumors demonstrate that the absolute protein levels of p53 and Rb increase within the nucleus in association with Tag. Functional inactivation of p53 and Rb impairs normal regulation of the cell cycle leading to increased proliferation and a loss of normal apoptotic responses. Tumor growth results from an imbalance between signals that stimulate cellular proliferation and those that result in the loss of cells through apoptosis. We have investigated additional changes in genetic pathways that regulate these two processes during mammary tumor progression.
Alterations in cell cycle regulation The inactivation of p53 by Tag leads to a loss of the cell cycle inhibitory functions of p21. This results in elevated levels of cyclins and cdk's (Figure 4) . The increased expression of these key regulators of the cell cycle leads to increased cellular proliferation associated with tumor progression. Normally, in response to various signals, p53 is upregulated which stimulates an elevation in p21 expression ultimately resulting in the suppression of cyclins, cdk's, and cell cycle progression. However, in this Tag transgenic model, induction of p21 by p53 does not occur due to the binding of p53 to Tag. The elevated levels of cyclins and cdk's in the transgenic mammary tumors are very similar to those reported for human breast cancer (Figure 4, arrows) . Recent gene therapy studies from our laboratory using an inducible retroviral delivery system have demonstrated that if p21 expression is restored in mammary tumor cells from the C3(1)/Tag transgenic mice, levels of cyclins and cdk's are reduced. When such cell lines are injected into nude mice and tumor growth is retarded when p21 expression is induced (Shibata et al., in preparation) . This transgenic model may be useful for testing therapies targeted against key regulators of the cell cycle.
Bi-phasic apoptotic response during mammary tumor progression: a role for bax Under normal conditions, a protective apoptotic response may prevent damaged cells from accumulating and forming tumors. We examined how levels of apoptosis change during dierent stages of mammary tumor progression (Shibata et al., 1996a . Approximately 1% of normal adult virgin female mammary ductal epithelial cells are undergoing apoptosis when assayed using the TUNEL method. The rate of apoptosis, however, rises dramatically in the stages of atypia and MIN to about 13% of all cells within the lesions. The levels of apoptosis fall to about 5% as the early lesions transition into invasive carcinomas. Thus, at early stages of tumor progression, a protective apoptotic response occurs which is repressed as these lesions become more aggressive.
Since Bcl-2 family members have been shown to be key regulators of apoptosis, we have examined expression patterns for Bcl-2 family members during mammary tumor progression in this transgenic model . The dramatic rise in apoptosis in the atypical and MIN lesions is associated with the elevated expression of the apoptosis inducer, bax. In order to test whether the expression of bax is, indeed, functionally signi®cant in regulating tumor progression, we generated mice carrying the C3(1)/Tag transgene in a background lacking one or both alleles of bax. In C3(1)/Tag mice lacking one or both alleles of bax, tumor formation occurred earlier with increased tumor multiplicity, increased rate of Shibata et al., 1999) . These results con®rmed that the level of Bax expression plays an important role in modulating tumor progression in this model.
Reduced expression of Bax does not aect the rates of cellular proliferation during any stage of mammary tumor progression. However, reductions in Bax expression lead to a signi®cant decrease in the rate of apoptosis, but only during the preneoplastic stage of tumor formation . The expression of Bax in this mammary cancer model is not dependent upon p53 expression, unlike studies performed in a transgenic model in which choroid plexus tumors develop (Yin et al., 1997) . This suggests that the regulation of bax by p53 may be tissue-speci®c.
Ongoing studies will attempt to determine what mechanisms are responsible for suppressing apoptosis as lesions transition into invasive carcinomas.
Testing therapeutic approaches
Since many biologic dierences exist between the mouse and the human, mouse models need to be validated for their usefulness as systems in which to test cancer therapies that may be applicable to human breast cancer. We have examined the therapeutic ecacy of several approaches using the C3(1)/Tag transgenic model.
Chemoprevention agents reduce tumor development
The ideal choice for reducing cancer morbidity and mortality is cancer prevention. Most chemoprevention studies to date have been preformed using chemical carcinogenesis models that have certain limitations. The molecular targets and their relevance to human cancer in chemically induced transformation are not well characterized. The mammary tumor phenotypes from such models generally do not have histologic characteristics which resemble human breast cancer (see article by Cardi et al., in this issue) , suggesting that the targeted cell compartment or oncogenic pathway may be dierent than those in human breast cancer.
Since the C3(1)/Tag transgenic mammary model shares several important features with human breast cancer, we have tested whether established chemopreventive agents are able to alter the natural history of tumor development in this model. The results of these studies demonstrate that both di-¯uoro-methyl ornithine (DFMO), hi-hydroepiandrosterone (DHEA) (Green et al., manuscript in preparation), and 9-cis retinoic acid (Wu et al., submitted) are able to signi®cantly reduce the incidence, multiplicity and volume of tumor growth in this transgenic model. This transgenic model may be useful for screening other selected chemopreventive agents for their ecacy in inhibiting the development and/or progression of mammary cancer.
Immunotherapy: regression of tumors using IL-2/IL-12 pulse therapy Since the direct targeting of tumor cells using gene therapy approaches has several important technical limitations, we have focused on approaches in which the immune system may be stimulated to destroy cancerous cells in this transgenic model. The advantage of using a transgenic model for these types of studies over xenograft models is that tumors arise spontaneously in the appropriate organ in an animal. The immune system is conditioned by the entire process of tumor development and progression.
Various eorts to overcome immune tolerance to the SV40 Tag expressed in this model by vaccination have been unsuccessful. Tumor cell lines developed from the mammary tumors fail to elicit anti-tumor protection despite the engineered overexpression of granulocytemacrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), and the co-stimulatory molecule B-7 with or without the enhancing eect of cotreatment with anti-CTLA-4 (unpublished data). These approaches have, however, been successful when applied to xenograft systems (Hodi and Drano, 1998; Hurwitz et al., 1998) .
In contrast, experimental trials using IL-12 pulse IL-2 combination cytokine therapy for the transgenic mammary tumors have resulted in a signi®cant impairment of tumor progression ( Figure 6 ) and regression of the majority of established tumors (Table 1 ; Wigginton et al., submitted). Interestingly, this eect does not appear to involve immune memory as new tumors develop at dierent sites within the mammary glands of mice where tumors regressed following termination of the IL-2/IL-12 therapy. This dramatic anti-tumor response may be mediated, in part, by anti-angiogenic eects of IL-12 (Voest et al., 1995) . Recent unpublished studies have also demonstrated that the anti-angiogenic compound endostatin can reduce mammary tumor incidence and growth in this model (S Ramakrishnan, manuscript in preparation).
Summary
The C3(1) regulatory sequences direct Tag expression to the ductal epithelial and TDLU in virgin animals. This transgenic model for mammary cancer demonstrates several important features that are similar to those observed in human breast cancer. These include the progressive histologic development of carcinomas in 100% of female mice (resembling lesions described as human in®ltrating ductal carcinomas) over the course of several months, passing through an Genomic and molecular alterations during stages of tumor progression can be studied. The Tag-induced transformation process leads to alterations in the expression of cell cycle genes as are similarly observed in human breast cancer. This model appears useful for testing novel therapeutic strategies.
